Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production
Facility

EQS-News: Eckert & Ziegler SE / Key word(s): Alliance/Miscellaneous
Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production
Facility

19.06.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

June 19, 2024 - Berlin, Germany and e, Czech Republic - Eckert & Ziegler
Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear
Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky,
'UJF'), announces the grand opening of a pioneering Actinium-225 (Ac-225)
production facility. This milestone, celebrated yesterday with an official
ceremony featuring Czech Prime Minister Petr Fiala, marks the culmination of
a longstanding partnership between Eckert & Ziegler and UJF. The facility is
now close to operational readiness, and after additional testing, commercial
production is slated to commence at the beginning of Q3/2024.

Currently, Ac-225-based radiopharmaceuticals are under clinical
investigation for various cancers, including prostate tumors, colorectal
cancer, and leukemia. A substantial increase in the demand for Ac-225 is
projected over the next decade, driven by its expanding clinical
applications and the promising results seen in ongoing trials. Despite its
therapeutic promise, sufficient quantities of Ac-225 remain scarce.

'Eckert & Ziegler, in conjunction with UJF, has explored one of the most
promising cyclotron-based production pathways for Ac-225,' said Dr. Lutz
Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH. 'Our
collaboration signifies a major leap forward in isotope production,
addressing the critical shortage of this isotope poised to revolutionize
modern oncology.'

The newly inaugurated laboratory will leverage cutting-edge technologies,
including a customized production line provided by Isotope Technologies
Dresden GmbH, which represents the Plant Engineering business of Eckert &
Ziegler. Radium-226, necessary for irradiation processes, will also be
supplied by Eckert & Ziegler.

'Today's opening marks a significant achievement in our collaboration with
Eckert & Ziegler,' commented Prof. Ondej Lebeda, Head of Department of
Radiopharmaceuticals at UJF. 'This new facility is a testament to our joint
dedication to innovation in the therapeutic landscape for many cancer
patients.'

Actinium-225 has emerged as a highly promising agent in the targeted therapy
of small tumors and metastases. Its high-energy cascade of alpha particles
with short penetration depths allows for precise targeting of tumor cells,
including difficult-to-reach micro metastases, while minimizing impact on
surrounding healthy tissue.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist
in isotope-related components for nuclear medicine and radiation therapy.
The company offers a broad range of services and products for the
radiopharmaceutical industry, from early development work to contract
manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700)
are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About UJF
The Nuclear Physics Institute of the Czech Academy of Sciences is a public
research institution that conducts research in a broad field of nuclear
physics, both experimental and theoretical. Its Department of
radiopharmaceuticals focuses on the investigation and production of novel
medical radionuclides as well as radionuclides important for physical
research.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com


---------------------------------------------------------------------------

19.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Eckert & Ziegler SE
                   Robert-Rössle-Str.10
                   13125 Berlin
                   Germany
   Phone:          +49 30 941084-138
   Fax:            +49 30 941084-0
   Internet:       www.ezag.de
   ISIN:           DE0005659700
   WKN:            565970
   Indices:        SDAX, TecDax,
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1928009

End of News EQS News Service
---------------------------------------------------------------------------

1928009 19.06.2024 CET/CEST